Correlation Between Blueprint Medicines and Monte Rosa

Can any of the company-specific risk be diversified away by investing in both Blueprint Medicines and Monte Rosa at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Blueprint Medicines and Monte Rosa into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Blueprint Medicines Corp and Monte Rosa Therapeutics, you can compare the effects of market volatilities on Blueprint Medicines and Monte Rosa and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Blueprint Medicines with a short position of Monte Rosa. Check out your portfolio center. Please also check ongoing floating volatility patterns of Blueprint Medicines and Monte Rosa.

Diversification Opportunities for Blueprint Medicines and Monte Rosa

-0.24

Correlation Coefficient

Blueprint Medicines  Monte Rosa

Very good diversification

The 3 months correlation between Blueprint and Monte is -0.24. Overlapping area represents the amount of risk that can be diversified away by holding Blueprint Medicines Corp and Monte Rosa Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Monte Rosa Therapeutics and Blueprint Medicines is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Blueprint Medicines Corp are associated (or correlated) with Monte Rosa. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Monte Rosa Therapeutics has no effect on the direction of Blueprint Medicines i.e., Blueprint Medicines and Monte Rosa go up and down completely randomly.

Pair Corralation between Blueprint Medicines and Monte Rosa

Given the investment horizon of 90 days Blueprint Medicines Corp is expected to generate 0.76 times more return on investment than Monte Rosa. However, Blueprint Medicines Corp is 1.32 times less risky than Monte Rosa. It trades about 0.03 of its potential returns per unit of risk. Monte Rosa Therapeutics is currently generating about -0.09 per unit of risk. If you would invest  8,682  in Blueprint Medicines Corp on December 29, 2024 and sell it today you would earn a total of  291.00  from holding Blueprint Medicines Corp or generate 3.35% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Blueprint Medicines Corp  vs.  Monte Rosa Therapeutics

Blueprint Medicines Corp

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Blueprint Medicines Corp are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of rather unfluctuating primary indicators, Blueprint Medicines may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Monte Rosa Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Monte Rosa Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in April 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Pair Trading with Blueprint Medicines and Monte Rosa

The main advantage of trading using opposite Blueprint Medicines and Monte Rosa positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Blueprint Medicines position performs unexpectedly, Monte Rosa can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Monte Rosa will offset losses from the drop in Monte Rosa's long position.

The idea behind Blueprint Medicines Corp and Monte Rosa Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.